Global Deferasirox Market, By Product Type (500mg, 250mg, 215 mg, Others), Application (β-thalassemia, Myelodysplastic Syndromes (MDS), Sickle Cell Disease (SCD), Aplastic Anemia (AA), Diamond-Blackfan Anemia (DBA), Others), Population Type (Adults, Paediatric), End-Users (Specialty Clinics, Hospitals, Home Care, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Deferasirox Market
Deferasirox market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.50% in the above-mentioned research forecast period. Increased incidence of anaemia worldwide and rise in inheritance of genetic disorders.
Moreover increasing the research and development and presence of pipeline products also boost up the market growth. Moreover, increasing healthcare expenditure and changing lifestyle leads to chronic disease act as opportunity for the market growth. But, sometimes adverse effect related to the drugs, inadequate knowledge of the medication and product recall may hamper the global deferasirox market.
Deferasirox is an oral iron chelator which is widely used for treatment of transfusional hemosiderosis in paediatrics and adult population. Clinical investigation reported that deferasirox is safe and effective for several kinds of anaemia’s. Anaemic patients are dependent on red blood cell transfusions which involves use of iron chelator, most commonly deferasirox among others. In the absence of iron chelating agent dysfunction of liver, heart and endocrine glands can take place and results in morbidity and mortality. The approval of deferasirox across different regions of world including Americas, Europe among others has provided market with a lucrative growth.
According to WHO it is estimated that approximately 1.6 billion people suffers from anaemia and is highly prevalent in preschool children and women among others. This population thus relies on red blood cell transfusion which involves the use of deferasirox and hence expected to provide market with the lucrative growth. It is also estimated that deferasirox market is growing with the CAGR of 6.60% in 2020.
The deferasirox market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Deferasirox Market Scope and Market Size
Deferasirox market is segmented on the basis of product type, application, population type, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the deferasirox market is segmented into 500mg, 250mg, 215 mg, others .
- On the basis of application, the deferasirox market is segmented into β-thalassemia, myelodysplastic syndromes (MDS), sickle cell disease (SCD), Aplastic Anemia (AA), Diamond-Blackfan Anemia (DBA), others.
- On the basis of population type, the deferasirox market is segmented into adults, paediatric.
- On the basis of end-users, the deferasirox market is segmented into specialty clinics, hospitals, home care, others.
- On the basis of distribution channel, the deferasirox market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Deferasirox Market Country Level Analysis
Deferasirox market is analysed and market size information is provided by product type, application, population type, end-users and distribution channel as referenced above.
The countries covered in the deferasirox market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the increasing patient’s population and favourable government support for product approval. Europe accounts the second largest market share due to increased use of deferasirox by heart surgeons among others and diverse distribution network. Asia-Pacific is expected to account for the largest market share over coming years for the deferasirox market as China is considered to be the largest producer of deferasirox and most of the countries import deferasirox APIs from China.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Deferasirox market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Deferasirox Market Share Analysis
Deferasirox market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Deferasirox market.
The major players covered in the deferasirox market are Cipla, Novartis Pharmaceuticals Corporation, NATCO Pharma Limited, Sun Pharmaceutical Industries Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Alkaloids Corporation, Neuland Laboratories Ltd., Medilux Laboratories Pvt. Ltd., Parabolic Drugs Ltd., ERREGIERRE S.p.A., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Jubilant Pharma Limited, Aurobindo Pharma, Alembic Pharmaceuticals Limited, BDR Pharmaceuticals Internationals Pvt. Ltd., Optimus Pharma. among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-